OCC 12.6% 49.0¢ orthocell limited

From the Managing Director....

  1. 260 Posts.
    lightbulb Created with Sketch. 38
    Email received today....

    IMO, Press and greater awareness is what will grow the company and its share price.

    As a valued supporter of Orthocell, I hope you were as happy us our team to see the market’s response to this week's announcement of clinical results for the use of our collagen medical device, CelGro®, to assist with surgery to repair peripheral nerve damage.

    Our share price was up by over 356% off the back of this news at market close on Wednesday, which is an overwhelming endorsement of the potential for CelGro® to aid complex and life-changing surgery for nerve repair. Patients and surgeons involved in our study have certainly detailed its merits, and we look forward to working closely with them to bring this technology to more people around the world.

    On Wednesday our team was in Sydney attending an investor event and over the past two days we've been meeting with senior journalists to share detailed insights into this promising clinical trial program. The announcement has already made plenty of headlines too.

    A snapshot of media coverage:

    • The West Australian, Orthocell shares quadruple on CelGro nerve regeneration trials in Perth’: see HERE
    • Business News, ‘Orthocell soars 356% on test results’: see HERE
    • Small Caps, Orthocell unveils first clinical trial results for nerve regeneration platform CelGro’: see HERE
    • The Motley Fool, Why the Orthocell share price is up more than 200% today’: see HERE
    • *, ‘Patients are saying Orthocell has fixed their damaged nerves, shares go ballistic’: see HERE
    Investment advisory firm Argonaut has also published a research note with a ‘speculative buy’ recommendation:
    • You may view the full report HERE or read the following summary:

    OCC announced that the first four patients had completed the CelGro® nerve regeneration trial with good results and patients treated have reported an 83% improvement in muscle power. The use of Celgro® improves outcomes by increasing the strength and quality of the repair as well as making the surgery easier to perform. Celgro ® creates a pathway for the nerves to regenerate along and this allows for the tensionless guiding of the regeneration of the nerve cells. The study is being undertaken at the St John of God Subiaco Hospital in Perth. The peripheral nerve repair market is large with over 20m people suffering from injuries in the US alone. We maintain our Speculative Buy Recommendation.

    We are so appreciative of your support and look forward to keeping you updated with our progress. Have a great weekend!

    With thanks,

    Paul Anderson

    Managing Director, Orthocell Limited

watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Mkt cap ! $74.95M
Open High Low Value Volume
50.0¢ 51.5¢ 46.5¢ $6.823M 13.81M

Buyers (Bids)

No. Vol. Price($)
3 33112 49.0¢

Sellers (Offers)

Price($) Vol. No.
49.5¢ 70296 2
View Market Depth
Last update - 16.10pm 19/06/2019 (20 minute delay) ?
0.055 ( 13.3 %)
Open High Low Volume
48.0¢ 52.0¢ 46.0¢ 5753902
Last updated 15.59pm 19/06/2019 (live) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.